EA201000486A1 - Ингибитор белка, активирующего 5-липоксигеназу (flap) - Google Patents

Ингибитор белка, активирующего 5-липоксигеназу (flap)

Info

Publication number
EA201000486A1
EA201000486A1 EA201000486A EA201000486A EA201000486A1 EA 201000486 A1 EA201000486 A1 EA 201000486A1 EA 201000486 A EA201000486 A EA 201000486A EA 201000486 A EA201000486 A EA 201000486A EA 201000486 A1 EA201000486 A1 EA 201000486A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lipoxygenase
flap
inhibitor
leukotriene
diseases
Prior art date
Application number
EA201000486A
Other languages
English (en)
Inventor
Мелисса Вирджиния Револински
Кевин Мюррэй Шааб
Кристофер Дэвид Кинг
Джиллиан Ф. Эванс
Петпибун Пеппи Прэсит
Джон Говард Хатчинсон
Николас Саймон Сток
Original Assignee
Амира Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амира Фармасьютикалз, Инк. filed Critical Амира Фармасьютикалз, Инк.
Publication of EA201000486A1 publication Critical patent/EA201000486A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Описаны способы синтеза 3-[5-(пиридин-2-илметокси)-3-(2-метил-2-пропилтио)-1-[4-(2-метоксипиридин-5-ил)бензил]индол-2-ил]-2,2-диметилпропионовой кислоты, ее фармацевтически приемлемых солей, фармацевтически приемлемых сольватов. Также описаны фармацевтические композиции, подходящие для перорального введения млекопитающему, а также способы применения таких пероральных фармацевтических композиций для лечения респираторных состояний или заболеваний, а также других лейкотриензависимых или лейкотриенопосредованных состояний или заболеваний.
EA201000486A 2007-10-26 2008-10-24 Ингибитор белка, активирующего 5-липоксигеназу (flap) EA201000486A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98311907P 2007-10-26 2007-10-26
US98312407P 2007-10-26 2007-10-26
PCT/US2008/081190 WO2009055721A2 (en) 2007-10-26 2008-10-24 5-lipoxygenase activating protein (flap) inhibitor

Publications (1)

Publication Number Publication Date
EA201000486A1 true EA201000486A1 (ru) 2010-12-30

Family

ID=40580422

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000486A EA201000486A1 (ru) 2007-10-26 2008-10-24 Ингибитор белка, активирующего 5-липоксигеназу (flap)

Country Status (17)

Country Link
US (1) US8697730B2 (ru)
EP (1) EP2212312A4 (ru)
JP (1) JP2011500846A (ru)
KR (1) KR20100080561A (ru)
CN (1) CN101910154A (ru)
AR (1) AR068947A1 (ru)
AU (1) AU2008316615A1 (ru)
BR (1) BRPI0818831A2 (ru)
CA (1) CA2702798A1 (ru)
CL (1) CL2008003181A1 (ru)
EA (1) EA201000486A1 (ru)
MX (1) MX2010004501A (ru)
PE (1) PE20090948A1 (ru)
TW (1) TW200920369A (ru)
UY (1) UY31431A1 (ru)
WO (1) WO2009055721A2 (ru)
ZA (1) ZA201002692B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
JP2010511632A (ja) * 2006-11-30 2010-04-15 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質インヒビターおよび一酸化窒素モジュレーターを含んでいる組成物および治療法
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
TWI453202B (zh) * 2010-03-23 2014-09-21 Scinopharm Taiwan Ltd 製備拉帕替尼之方法及中間體
KR101137929B1 (ko) * 2010-05-31 2012-05-09 에스케이하이닉스 주식회사 비휘발성 메모리 장치 및 그 제조 방법
WO2014031586A2 (en) * 2012-08-20 2014-02-27 Tallikut Pharmaceuticals, Inc. Methods for treating cardiovascular diseases
WO2014204511A2 (en) 2013-06-18 2014-12-24 Isonea Limited Compliance monitoring for asthma inhalers
CN105814035B (zh) 2013-12-13 2018-02-02 豪夫迈·罗氏有限公司 布鲁顿氏酪氨酸激酶抑制剂
RU2648236C2 (ru) 2013-12-13 2018-03-23 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
US9802920B2 (en) 2013-12-13 2017-10-31 Hoffman-La Roche Inc. Inhibitors of bruton's tyrosine kinase
WO2015120038A1 (en) 2014-02-04 2015-08-13 Bioscience Pharma Partners, Llc Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system
SG11201804776SA (en) * 2015-12-08 2018-07-30 Biomatrica Inc Reduction of erythrocyte sedimentation rate
CN112126986B (zh) * 2020-04-30 2023-07-18 苏州京脉生物科技有限公司 一种定量miRNA的测序文库制备和分析方法
CN115267002A (zh) * 2022-08-08 2022-11-01 江苏慧聚药业股份有限公司 Gc-ms/ms联用测定醰露替尼中游离肼的方法

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2431491A1 (fr) 1978-07-18 1980-02-15 Delalande Sa Nouveaux derives aminoalkoxy-5 benzofurannes et indoles, leur procede de preparation et leur application en therapeutique
DK151884C (da) 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
JPS60123485A (ja) 1983-12-08 1985-07-02 Yoshitomi Pharmaceut Ind Ltd インド−ル−３−カルボキサミド誘導体
IE58870B1 (en) 1985-03-08 1993-11-17 Leo Pharm Prod Ltd Pyridine derivatives
US5109009A (en) 1985-03-08 1992-04-28 Leo Pharmaceutical Products Ltd. Quinoline and pyridine compounds and inhibition of 5-lipoxygenases therewith
US5225421A (en) 1986-12-17 1993-07-06 Merck Frosst Canada, Inc. 3-hetero-substituted-N-benzyl-indoles and medical methods of use therefor
US5081138A (en) * 1986-12-17 1992-01-14 Merck Frosst Canada, Inc. 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith
US5232916A (en) 1988-06-27 1993-08-03 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
CA1337427C (en) 1989-08-22 1995-10-24 Merck Frosst Canada Incorporated (quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
US5272145A (en) 1989-08-22 1993-12-21 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
US5204344A (en) 1989-08-22 1993-04-20 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
NZ234883A (en) 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
US5252585A (en) 1992-02-03 1993-10-12 Merck Frosst Canada, Inc. Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes
US5420289A (en) 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5229516A (en) 1989-10-27 1993-07-20 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
CA2032253C (en) 1989-12-15 2000-11-28 John W. Gillard 5-lipoxygenase activating protein
US5093356A (en) 1990-01-16 1992-03-03 Merck Frosst Canada, Inc. Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
US5081145A (en) 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
JPH0764841B2 (ja) 1990-10-03 1995-07-12 ファイザー製薬株式会社 インドール誘導体およびその用途
US5182367A (en) 1990-11-30 1993-01-26 Merck & Co., Inc. 5-lipoxygenase activating protein
GB9108811D0 (en) 1991-04-24 1991-06-12 Erba Carlo Spa N-imidazolyl derivatives of substituted indole
US5202321A (en) 1991-06-13 1993-04-13 Merck Frosst Canada, Inc. Thiopyrano[2,3,4-c,d]indoles as inhibitors of leukotriene biosynthesis
JPH06100551A (ja) 1991-09-06 1994-04-12 Dainippon Ink & Chem Inc 光学活性な２，５置換テトラヒドロフラン誘導体、その製造方法、その誘導体を含む液晶組成物及び液晶表示素子
US5308850A (en) 1991-09-30 1994-05-03 Merck Frosst Canada, Inc. (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5273980A (en) 1991-09-30 1993-12-28 Merck Frosst Canada Inc. Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5290798A (en) 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
CA2079374C (en) 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5190968A (en) 1991-09-30 1993-03-02 Merck Frosst Canada, Inc. (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5389650A (en) 1991-09-30 1995-02-14 Merck Frosst Canada, Inc. (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
US5254567A (en) 1991-11-15 1993-10-19 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds which have useful pharmaceutical utility
CH683522A5 (de) 1992-03-13 1994-03-31 Hoffmann La Roche Verfahren zur Herstellung von Diarylen.
EP0597112A4 (en) 1992-03-27 1994-06-22 Kyoto Pharma Ind Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor.
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
JPH0658881A (ja) 1992-06-12 1994-03-04 Mitsubishi Rayon Co Ltd 光学活性化合物の絶対配置判定法、絶対配置判定用試薬及び絶対配置判定装置
US5334719A (en) 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
US5314898A (en) 1992-06-29 1994-05-24 Merck & Co., Inc. Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene biosynthesis
US5288743A (en) 1992-11-20 1994-02-22 Abbott Laboratories Indole carboxylate derivatives which inhibit leukotriene biosynthesis
JP3457694B2 (ja) 1993-02-04 2003-10-20 第一製薬株式会社 インフルエンザ感染予防・治療薬
US5374635A (en) 1993-03-29 1994-12-20 Merck Frosst Canada, Inc. Furo[3,2-b]pyridines and thieno[3,2-b]pyridines as inhibitors of leukotriene biosynthesis
JPH075651A (ja) 1993-06-14 1995-01-10 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料の処理方法
DE4338770A1 (de) 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
US5399699A (en) 1994-01-24 1995-03-21 Abbott Laboratories Indole iminooxy derivatives which inhibit leukotriene biosynthesis
US5420282A (en) 1994-02-15 1995-05-30 Abbott Laboratories Thiopyrano(2,3,4-c,d) indolyloxime ether alkylcarboxylates
US5696076A (en) 1994-06-22 1997-12-09 Human Genome Sciences, Inc. 5-lipoxygenase-activating protein II
FR2721610B1 (fr) 1994-06-28 1996-08-23 Adir Nouveaux dérivés (thia)cycloalkyl [b] indoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JPH0820532A (ja) 1994-07-05 1996-01-23 Dai Ichi Seiyaku Co Ltd 抗膵炎剤
TW396200B (en) 1994-10-19 2000-07-01 Sumitomo Chemical Co Liquid crystal composition and liquid crystal element containing such composition
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
JPH092977A (ja) 1995-06-21 1997-01-07 Dai Ichi Seiyaku Co Ltd 経口投与用医薬組成物
US5750558A (en) 1996-06-06 1998-05-12 Abbott Laboratories Oxime derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
US5877329A (en) 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
JPH1180032A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 複合体
JPH11193265A (ja) 1997-12-26 1999-07-21 Dai Ichi Seiyaku Co Ltd ３−（７−アミジノ−２−ナフチル）−２−フェニルプロピオン酸誘導体の塩
JPH11189531A (ja) 1997-12-26 1999-07-13 Dai Ichi Seiyaku Co Ltd 経粘膜投与用医薬組成物
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU768721B2 (en) 1998-04-15 2004-01-08 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma
US6867209B1 (en) 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
JP2000007590A (ja) 1998-06-23 2000-01-11 Daicel Chem Ind Ltd 置換芳香族化合物の製造方法
JP2000302671A (ja) 1999-04-27 2000-10-31 Hitoshi Sezaki 経口投与用医薬組成物
DE19948417A1 (de) 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
JP2001139462A (ja) 1999-11-10 2001-05-22 Dai Ichi Seiyaku Co Ltd 新規製剤
US20010039037A1 (en) 2000-04-05 2001-11-08 Lee Harland Novel polypeptide
AU2001259707A1 (en) 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
JP2002226429A (ja) 2001-02-06 2002-08-14 Fuji Photo Film Co Ltd アクリル酸エステル化合物の製造方法
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
USH2153H1 (en) 2002-04-24 2006-04-04 Smithkline Beecham Corp. Association of asthma with polymorphisms in the cysteinyl leukotriene 2 receptor
JPWO2004000795A1 (ja) 2002-06-20 2005-10-20 協和醗酵工業株式会社 ビニルパーフルオロアルカンスルホン酸エステル誘導体の製造法
ES2342596T3 (es) 2002-08-29 2010-07-09 MERCK SHARP & DOHME CORP. Indoles con actividad anti-diabetica.
WO2004048331A1 (en) 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
US20040198800A1 (en) 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
GB0301350D0 (en) 2003-01-21 2003-02-19 Merck Sharp & Dohme Therapeutic agents
JP4513351B2 (ja) 2003-02-12 2010-07-28 チッソ株式会社 結合基にフッ素化されたアルキル基を有する液晶性化合物、液晶組成物および液晶表示素子
EP1600440A1 (en) 2003-03-06 2005-11-30 Ono Pharmaceutical Co., Ltd. Indole derivative compounds and drugs containing the compounds as the active ingredient
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
WO2004108671A1 (en) 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
US7629467B2 (en) 2003-07-24 2009-12-08 Merck & Co., Inc. Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
WO2005019381A1 (en) 2003-08-25 2005-03-03 Merck Patent Gmbh Liquid crystalline medium
WO2005023246A1 (en) 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
JP4363133B2 (ja) 2003-09-09 2009-11-11 東洋インキ製造株式会社 有機エレクトロルミネッセンス用素子材料およびそれを用いた有機エレクトロルミネッセンス素子
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
ES2299906T3 (es) 2003-11-25 2008-06-01 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisomas.
JPWO2005054213A1 (ja) 2003-12-02 2007-12-06 塩野義製薬株式会社 ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
DE602004023762D1 (de) 2003-12-03 2009-12-03 Merck Sharp & Dohme Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
JP5142450B2 (ja) 2003-12-25 2013-02-13 徹也 西尾 ジアミノ化合物、ビニル化合物、高分子化合物、配向膜、該配向膜を用いた有機半導体装置、導電性高分子、該導電性高分子を使用したエレクトロルミネッセンス素子、液晶配向膜、及び該液晶配向膜を用いた光学素子
WO2005066157A1 (en) 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
JP2005194250A (ja) 2004-01-09 2005-07-21 Sumitomo Chemical Takeda Agro Co Ltd トリアゾール化合物、その製造法および用途
EP1727533A1 (en) 2004-02-26 2006-12-06 Merck & Co., Inc. Use of cysteinyl leukotriene 2 receptor antagonists
SI1756096T1 (sl) 2004-05-03 2009-10-31 Hoffmann La Roche Indolilni derivati kot modulatorji jetrnega x receptorja
BRPI0512253A (pt) 2004-06-18 2008-02-19 Biolipox Ab composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
CN1980659A (zh) 2004-07-02 2007-06-13 默克公司 具有抗糖尿病活性的吲哚类
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006041961A1 (en) 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
AU2006205850A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
US8097623B2 (en) 2005-01-19 2012-01-17 Biolipox Ab Indoles useful in the treatment of inflammation
JP2008527030A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
JP2008527027A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
WO2006077365A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
CA2600860A1 (en) 2005-03-09 2006-09-21 Merck & Co., Inc. Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
RU2453540C2 (ru) 2005-04-21 2012-06-20 Лаборатуар Сероно С.А. 2,3-замещенные пиразинсульфонамиды в качестве ингибиторов crth2
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2007047204A1 (en) 2005-10-11 2007-04-26 University Of Pittsburgh Isotopically-labeled benzofuran compounds as imagingagents foramyloidogenic proteins
US20070219206A1 (en) * 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070244128A1 (en) 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
UY29896A1 (es) 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
UY29892A1 (es) 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
CN101595084B (zh) 2006-06-29 2013-01-02 金克斯医药品有限公司 用于调整激酶级联的二芳基组合物和方法
JP2009023986A (ja) 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
DK2848610T3 (da) 2006-11-15 2017-11-06 Ym Biosciences Australia Pty Hæmmere af kinaseaktivitet
JP2010511632A (ja) 2006-11-30 2010-04-15 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質インヒビターおよび一酸化窒素モジュレーターを含んでいる組成物および治療法
US20100204282A1 (en) 2007-02-05 2010-08-12 Hutchinson John H Reverse indoles as 5-lipoxygenase-activating protein (FLAP) inhibitors
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
WO2009002746A1 (en) 2007-06-22 2008-12-31 Decode Genetics Ehf. Dosing schedules of leukotriene synthesis inhibitors for human therapy
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US20120220779A1 (en) 2009-11-03 2012-08-30 Claire Frances Crawford Novel Processes

Also Published As

Publication number Publication date
PE20090948A1 (es) 2009-07-27
AU2008316615A1 (en) 2009-04-30
ZA201002692B (en) 2011-06-29
TW200920369A (en) 2009-05-16
CA2702798A1 (en) 2009-04-30
MX2010004501A (es) 2010-05-13
EP2212312A4 (en) 2011-10-05
WO2009055721A2 (en) 2009-04-30
CN101910154A (zh) 2010-12-08
US20100075934A1 (en) 2010-03-25
JP2011500846A (ja) 2011-01-06
US8697730B2 (en) 2014-04-15
BRPI0818831A2 (pt) 2015-04-22
WO2009055721A3 (en) 2009-08-20
AR068947A1 (es) 2009-12-16
EP2212312A2 (en) 2010-08-04
CL2008003181A1 (es) 2009-03-06
UY31431A1 (es) 2009-05-29
KR20100080561A (ko) 2010-07-08

Similar Documents

Publication Publication Date Title
EA201000486A1 (ru) Ингибитор белка, активирующего 5-липоксигеназу (flap)
EA201001668A1 (ru) Ингибитор белка, активирующего 5-липоксигеназу
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
ATE517882T1 (de) Chinolinderivate
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
WO2008130879A3 (en) Tetrahydroindole and tetrahydroindazole derivatives
MY139941A (en) Indole derivatives
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
TW200616953A (en) Indole, indazole or indoline derivatives
GEP20156348B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
NZ599513A (en) Compounds for the treatment of dyslipidemia and related diseases
WO2007135527A3 (en) Benzimidazolyl compounds
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
EA201390717A1 (ru) 3-(аминоарил)пиридиновые соединения
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
UA96575C2 (en) Process for the preparation of olmesartan medoxomil
WO2006077024A3 (en) 5-aminoindole derivatives
ATE399156T1 (de) Neue indol- oder benzimidazol-derivate
NO20080750L (no) (Indol-3-YL)-heterocykelderivater som agonister av cannabinoid CB1 reseptor
NZ600266A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
EA201070916A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты